ARTICLE | Clinical News
BM32: Phase IIa data
June 18, 2012 7:00 AM UTC
Top-line data from a double-blind, placebo-controlled, Austrian Phase IIa trial in 70 patients with grass pollen allergy showed that 3 injections of once-monthly subcutaneous BM32 significantly reduce...